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Beyond the disorders recognized as mitochondrial diseases, abnormalities in function and/or ultrastructure of mitochondria have
been reported in several unrelated pathologies. These encompass ageing, malformations, and a number of genetic or acquired
diseases, as diabetes and cardiologic, haematologic, organ-specific (e.g., eye or liver), neurologic and psychiatric, autoimmune, and
dermatologic disorders. The mechanistic grounds for mitochondrial dysfunction (MDF) along with the occurrence of oxidative
stress (OS) have been investigated within the pathogenesis of individual disorders or in groups of interrelated disorders.We attempt
to review broad-ranging pathologies that involvemitochondrial-specific deficiencies or rely on cytosol-derived prooxidant states or
on autoimmune-inducedmitochondrial damage.The established knowledge in these subjects warrants studies aimed at elucidating
several open questions that are highlighted in the present review. The relevance of OS and MDF in different pathologies may
establish the grounds for chemoprevention trials aimed at compensating OS/MDF by means of antioxidants and mitochondrial
nutrients.
1. Introduction
Mitochondria have long been recognized as the main site of
bioenergetic pathways [1, 2]. After the early investigations on
OS in 1980s, implications for an involvement ofmitochondria
in OS were found in early 1990s [3, 4], which associatedMDF
with OS in the pathogenesis of some diseases, such as mito-
chondrial myopathies (progressive external ophthalmople-
gia) and Parkinson’s disease [5, 6].Those early studies opened
multiple research avenues toward growing and currently
thriving investigations in a number of diseases, or disease
groups, pertaining different medical disciplines. Beyond the
focus on individual pathologies, or limited groups of diseases
sharing molecular or clinical affinities, the present review is
aimed at attempting a survey of OS/MDF across a broader
range of different disorders that have been investigated for the
occurrence of OS/MDF as pathogenetic mechanisms either
directly or concomitant with other inborn or exogenous
causes of disease.
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2. Mitochondrial Diseases
A number of studies led to identifying a set of different dis-
orders affectingmitochondrial function and/or structure that
are collectively termed mitochondrial diseases (MDs) [7]. As
shown inTable 1, primarymitochondrial diseases (PMDs) are
caused by mitochondrial DNA (mtDNA) defects, while sec-
ondary mitochondrial diseases (SMDs) are caused by defects
of nuclear genes encoding mitochondrial (or mitochondria-
related) proteins [8]. In both cases,MDs have been associated
with different deficiencies in mitochondrial functions and
evidence has been reported for prooxidant states as clinical
and/or molecular OS hallmarks [9–34]. EndogenousMDF in
PMDs has been shown to affect oxidative phosphorylation
(OXPHOS) activities in PMDs (Complex I, III, and/or IV),
as in mitochondrial myopathy, encephalomyopathy, lactic
acidosis, stroke-like symptoms (MELAS) [15–19], Kearns-
Sayre syndrome [23], chronic progressive external ophthal-
moplegia (CPEO) [24, 25], and Pearson syndrome [26, 27].
An overall OXPHOS inhibition has also been observed in
SMDs, as Alpers-Huttenlocher syndrome, along with poly-
merase 𝛾 mutations [28–31]. Implications for OS in these
disorders have been reported in terms of COQ2 gene defect,
encoding for OH-benzoate polyprenyltransferase catalyzing
a major step in coenzyme Q10 synthesis. As a result, lower-
than-normal CoQ10 levels were observed in mitochondrial
neurogastrointestinal encephalomyopathy (MNGIE), a SMD
and CoQ10 deficiency syndrome, a rare condition that
causes MDF and includes a variety of clinical presentations
as encephalomyopathy, ataxia, and renal failure [32, 33].
Protective effects of either CoQ10 or of other antioxidants
were detected in Leber’s hereditary optic neuropathy (LHON)
[9–11], Leigh syndrome [12], neuropathy, ataxia, retinitis
pigmentosa and ptosis (NARP) [14], MELAS [18, 19], and
maternally inherited diabetes mellitus and deafness (MIDD)
[22].
Altogether, MDs are recognized to involve the respira-
tory chain, both controlled by nuclear DNA and mtDNA.
Mendelian mitochondrial defects can affect subunits of
respiratory chain complexes, mitochondrial assembly pro-
teins, mtDNA translation, phospholipid composition of the
inner mitochondrial membrane, or mitochondrial dynam-
ics or involve mtDNA maintenance, combining features of
mendelian and mitochondrial genetics [34].
Beyond MDs, a broad and growing number of disor-
ders have been investigated for the implications of OS in
their respective pathogenetic mechanisms with concurrent
involvement of MDF. Unlike strictly termed MDs, in most
cases the available implications of MDF are indirect, relying
on surrogate indicators, such as decreased levels ofmitochon-
drial cofactors, or altered mitochondrial membrane potential
(ΔΨ), or increased lactate/pyruvate ratio, or secondary mito-
chondrial damage as, for example, due to iron overload or
to antimitochondrial autoantibodies. Even so, the range of
MDF covers an extensive number of disorders that associate
OS/MDF in their pathogenetic mechanisms, as reported
previously for several disorders or groups of interrelated
disorders and discussed below in the present review.
3. Genetic Diseases
A number of genetic diseases (GDs) have been investigated
for the implications of OS/MDF in their pathogenesis, as
summarized in Table 2 [35–101]. The broad range of GDs
investigated in this context includes a set of cancer-prone
and/or ageing-related disorders and a number of GDs affect-
ing various tissues and organs, including CNS, blood, and
muscles.
3.1. Cancer-Prone and/or Early Ageing Diseases. These GDs
are characterized by an enhanced risk of malignancies that
are often more prevalent in a given disorder (e.g., myeloid
leukaemias in Fanconi anaemia, FA), and many of these GDs
exhibit propension to early ageing, which either affects the
whole organism (progerias, e.g., Werner syndrome,WS) or is
confined to given tissues, such as bonemarrow impairment or
neurodegeneration. A huge body of literature, omitted in the
present review, associates this disease group with deficiencies
inDNArepair, and themajority of research efforts—andmost
of funding resources—have been deployed to investigate
these GDs within the theorem of DNA repair deficiency, in
view of planning gene therapy protocols.
In the case of Down syndrome (DS), the trisomic
condition has been viewed beyond any effort of genetic
engineering, and any therapeutic approach has been mostly
confined to psychological and physical rehabilitation.
The involvement of OS in this disease group has been
reported since early studies in 1980s finding redox abnormal-
ities in cells from patients with DS [53], ataxia-telangiectasia
(AT) [39], or FA [54]. As for mitochondrial abnormalities, a
substantial body of literature has accrued for the implications
of MDF in this group of diseases (see below); thus the
occurrence of OS andMDF has been documented in cellular,
molecular, and animal studies and by in vivo evidence from
human patients.
3.1.1. Ataxia-Telangiectasia. An established body of literature
relates ATpathogenesis bothwithOS since 1983 [39] andwith
MDF. Evidence was provided for excess ROS production and
oxidative DNA damage, and for mitochondrial abnormali-
ties including ultrastructure aberrations, decreased ΔΨ and
mitophagy, and increased expression of respiratory enzymes
in AT cells [35–39].
3.1.2. Bloom Syndrome. Early studies suggested the occur-
rence of OS in Bloom syndrome (BS) [40, 41]. We have pre-
viously reported excess oxidative DNA damage (8-hydroxy-
2-deoxyguanosine, 8-OHdG) inWBC from BS patients, with
an unexpected decrease in glutathione disulfide : glutathione
(GSSG :GSH) ratio [42]. No reports were found to be eval-
uated regarding any MDF in BS phenotype, and this subject
warrants ad hoc investigations.
3.1.3. Cockayne Syndrome. Cockayne syndrome (CS) pheno-
type displays a set of OS hallmarks, such as excess reactive
oxygen species (ROS) production and DNA oxidative dam-
age, along with decreased 8-oxoguanine DNA glycosylase-1
(OGG1) expression [43, 44]. Mitochondrial abnormalities
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consisted of excess mitophagy [45], and Kamenisch and
Berneburg found that defective CSA and CSB proteins
localize to mitochondria, by decreasing interaction with
mitochondrial OGG1 [46].
3.1.4. Down Syndrome. Down syndrome (DS) represents one
of the best documented GDs for the established implications
of both OS and MDF in DS phenotype, both in vitro and in
vivo, namely, human trisomy 21 patients andmurineDSmod-
els, such as trisomy 16 [47–52]. Since the pioneering studies
dating back to 1980s [53], DS phenotype has been associated
with Cu,Zn-superoxide dismutase (SOD-1) overexpression.
Thus the ratio SOD-1 to catalase (CAT) plus glutathione per-
oxidase (GPx) is increased; hence more hydrogen peroxide
is generated by SOD-1 than CAT and GPx can catabolize,
giving rise to an OS positive feedback. Valenti et al. [50, 51]
investigated skin fibroblasts from DS patients, finding excess
ROS production alongwith a deficiency in Complex I activity
with the involvement of the cAMP/PKA signalling pathway
[50]. This group also reported that epigallocatechin-3-gallate
prevents OXPHOS deficit while promotes mitochondrial
biogenesis in DS fibroblasts [51]. Other authors reported on
MDF inDS, affecting Krebs cycle activities, CoQ10 deficiency
and mitochondrial ultrastructure in human DS cells and in
human patients [48, 49], and in trisomy 16 mice [52].
3.1.5. Fanconi Anaemia. Fanconi anaemia (FA) has been
associated with redox imbalances since early studies includ-
ing, among others, the pioneering report by Joenje et al.
[54]. Thereafter, a growing body of literature has established
a number of mechanistic implications of OS in the functions
of several proteins encoded by FA genes, as well as by in
vitro and animal studies, and in blood cells and biological
fluids from FA patients (reviewed in [55, 56]). Three inde-
pendent studies of MDF in FA cell lines of different genetic
subtypes provided evidence for abnormal ultrastructure and
function of mitochondria in FA cells [57–59]. Our recent
report on bone marrow cell transcripts from FA patients
revealed downregulation of genes involved in mitochondrial
functions, antioxidant activities, heat shock proteins, and
chelating proteins [60]. Thus, the role in the FA phenotype
of OS/MDF may be considered well established and awaits
consequent interventions in clinical management, in view of
preventing or delaying disease progression.
3.1.6. Hutchinson-Gilford Syndrome. Hutchinson-Gilford
syndrome (HGS) is a progeria displaying excess ROS pro-
duction, and increased mRNA levels and protein content
for mitochondrial Mn superoxide dismutase (SOD-2), along
with a drop in the ATP (50%) content of HGS fibroblasts
versus controls. Moreover, HGS cells showed defective
caspase-like proteasome activity, and DNA damage was
prevented by N-acetyl cysteine [61, 62].
3.1.7. Nijmegen Breakage Syndrome. Nijmegen breakage syn-
drome (NBS) features oxidative DNA damage resulting in
mitochondrial p53 accumulation and resistance to apoptosis,
and in poly (ADP-ribose) polymerase (PARP) hyperactiva-
tion resulting in NAD+ depletion [63, 64]. Krenzlin et al.
attributed the “extremely high incidence of malignancy
amongNBS patients to the combination of a primary double-
strand break repair deficiency with secondary oxidative DNA
damage” [64].
3.1.8. Rothmund-Thomson Syndrome. Rothmund-Thomson
syndrome (RTS) gene product RECQL4 localizes to the
nucleolus in response toOS. RTS fibroblasts exhibit increased
OS-related p38 MAP kinase; thus cell lifespan and growth
rate are increased by p38 MAP kinase inhibitor [65, 66].
Moreover, RECQL4 was found to localize to mitochondria,
and the loss of RECQL4 altersmitochondrial bioenergetics as
mitochondrial reserve capacity was depressed after RECQL4
knockdown [67].
3.1.9. Werner Syndrome. Werner syndrome (WS), also
termed “adult progeria” due to its late phenotypic onset,
has been extensively investigated for its relationships with
OS [68–70], and we reported the multiple involvements of
the defective WRN protein both in DNA stability and in
redox balance [70]. Mitochondrial ultrastructure anomalies
were found in cells from the WS mouse model, Wrn helicase
mutant mice (WrnDhel/Dhel) [68, 71]. Alterations in OS
endpoints were detected in blood cells and biological fluids
from WS patients to the highest extent compared to patients
with other OS-related diseases and versus healthy donors
[72].
3.1.10. Xeroderma Pigmentosum. Xeroderma pigmentosum
(XP) displays several OS features, including defective
repair of DNA oxidative damage (8,5󸀠-(S)-cyclo-2󸀠-deox-
yadenosine), while lipid peroxidation and protein glycation
are increased in cells and brains from XP patients, along
with reduced expression of SOD [73]. Mitochondrial abnor-
malities were exhibited in terms of defective mitochondrial
gene transcripts for 16 S rRNA, ATPase 6L, and lactate
dehydrogenase; moreover, lower-than-normal CoQ10 levels
were observed in serum from XP patients [74–77].
3.2. Neurological and Muscle Diseases
3.2.1. Adrenoleukodystrophy. This genetic disease is charac-
terized by progressive neurologic motor impairment and
displays a set of OS-related defects. OS markers include
decrease in GSH :GSSH ratio, excess lipid oxidation, and
decrease in total antioxidant defenses in symptomatic but
not in asymptomatic patients [78–80]. MDF was found to
include impairment in OXPHOS activities and a decrease
in Complex V, along with decreased ATP levels; moreover,
mitochondrial inner membrane potential dissipation was
reported [81]. A recent report found OXPHOS disruption
and mitochondrial depletion in ABCD1 null mouse, a mouse
model for adrenomyeloneuropathy [82].
3.2.2. Duchenne Muscular Dystrophy. Duchenne muscu-
lar dystrophy (DMD) displays a set of OS hallmarks
in terms of increased protein thiol oxidation, lipofuscin,
4-hydroxynonenal (4-HNE), and total hydroperoxides, with
decreased GSH, in cells and biological fluids from DMD
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patients [83, 84]. A concomitant MDF was suggested by
impaired OXPHOS activities and decrease in ATP synthesis
in the mdx mouse model for DMD [85].
3.2.3. Friedreich Ataxia. Friedreich ataxia displays a number
of MDF features, including decreased Complex I, II, and
III, aconitase, and CoQ10 levels, with mitochondrial Fe
overload [86, 87]. A concomitant OS condition was shown
by decreased vitamin E levels, Fe dysregulation, and hyper-
sensitivity to OS [88].
3.2.4. Huntington’s Disease. Huntington’s disease (HD) dis-
plays excess levels of brain protein carbonyls that are
decreased by CoQ10 administration [89]. Moreover, CoQ10
and creatine exert additive neuroprotective effects in HD
mice and rats. Evidence for MDF was provided by finding
excess NADPH oxidase (NOX) activity in human HD brains,
parallel with synaptosome fractions from cortex and striatum
of HD (140Q/140Q) mice, suggesting that increased NOX2
activity at lipid rafts is an early and major source of OS and
cell death in HD (140Q/140Q) neurons [89–92].
3.3. Other Genetic Diseases
3.3.1. Hyperhomocysteinaemia. The set of dysmetabolic
defects in hyperhomocysteinaemia (HHC) both include
MDF and OS [93–95]. Evidence for MDF was provided
by decreased ΔΨ, release of cytochrome-c and by increase
in mitochondrial matrix metalloproteinase [93, 94].
Implications of OS in HHC phenotype were shown by a
decrease in sulfhydryl groups and total antioxidant status in
plasma from HHC patients [95].
3.3.2. Sickle Cell Disease. Sickle cell disease (SCD) is mainly
characterized by sickle erythrocyte haemolysis resulting in
excess free Fe release that, as such, triggers OS. Thus,
excess ROS production and advanced glycation end products
(AGEs) were observed, with a concomitant GSH decrease
[96, 97]. An early paper reported on Fe-laden mitochondria
in sickled reticulocytes from SCDpatients [98], and that early
observation warrants further up-to-date investigations.
3.3.3. Thalassaemia. Thalassaemic patients showed oxidative
damage to lipid membranes, proteins, and DNA (WBC
8-OHdG) [99]. Mitochondrial damage was found to be
induced by non-transferrin-bound Fe, resulting in decreased
ΔΨ [100]. The observation of lower-than-normal levels of
l-carnitine also might be related to MDF [101].
4. Ageing and Ageing-Related
Degenerative Disorders
4.1. Ageing. Ageing is not regarded as a disease per se;
however several diseases have been associated with ageing,
as summarized in Table 3. Extensive and multi-decade-long
literature relates ageing to OS and MDF. As a brief selection
of this vast body of evidence, OS and nitrosative stress (NS)
hallmarks were shown by excess age-related oxidative DNA
damage, decreased GSH :GSSG ratio, increased inducible
NOS (iNOS) expression, and Fe accumulation [102–104].
A major focus on age-related MDF has resulted in an
established body of evidence including, among others, MDF
related to decrease in both OXPHOS activities (Complexes
I and IV) and Krebs cycle (downregulated pyruvate dehy-
drogenase along with overexpressed pyruvate kinase and
lactate dehydrogenase).Moreover, Prdx3 overoxidization and
mtDNA damage were reported [105–107].
4.2. Cardiovascular Diseases. Also cardiovascular diseases
(CVDs) have been broadly investigated—since early
studies—for the implications of OS/MDF in their patho-
genesis. Double-edged physiopathological roles for ROS
and reactive nitrogen species (RNS) are recognized, both
as mediators of cardiovascular functions and as effectors
of cardiovascular tissue damage [108, 109]. Among the
best recognized OS/NS hallmarks, excess lipid and protein
oxidation, altered NADPH regulation, and peroxynitrite
formation have been reported [108, 109]. Well-established
implications of MDF are available for CVDs, including
reports on mitochondrial aberrations, SOD-2 upregulation,
and mtDNA mutations in atherosclerotic plaques [110–113].
4.3. Metabolic Syndrome. Extensive evidence for OS/MDF
implications in metabolic syndrome has been accumulating
in recent years [114–119]. Evidence forOS-related changeswas
provided by excess TBARS and plasma 8-isoprostanes, along
with decrease in total antioxidative activity and in serum
vitaminsC andE.An involvement forMDF in these disorders
was found by downregulated Complex I, NADPH oxidase,
and in SIRT3, leading to excess mitochondrial protein acety-
lation; also observed was a decreased mtDNA copy number
and dysregulated carnitine palmitoyltransferase [114–119].
4.4. Osteoarthritis. Osteoarthritis (OA) features a number of
OS hallmarks, as decreased total antioxidant capacity, thiol
levels, catalase activity, and prolidase activity, along with
increased total peroxides and lipid peroxides, and myeloper-
oxidase overexpression [120]. Evidence for MDF in OA
patients was shown by downregulated SOD-2 andComplexes
I, II, and III, and by mitochondrial genome dysregulation,
with 17 upregulated and 9 downregulated genes [121–124].
4.5. Diabetes. Type 2 diabetes has been extensively investi-
gated for its pathogenetic implications of OS/MDF. Diabetic
patients displayed excess oxidation of proteins, lipids, and
DNA, that is, increased levels of 15-F2t-iso-prostaglandin
and 4-HNE, as products of lipid oxidation, and advanced
oxidation protein products, advanced glycation end products
(AGEs), excess oxidative DNA damage (8-OHdG), upreg-
ulated NADPH oxidase, Trx and HSP70, and decreased
GSH :GSSG ratio [125–128]. Downregulation of Complex
I and/or IV, and of SOD-2 point to MDF occurrence in
diabetic patients [129–133]. It should be recalled that Type
2 diabetes occurs as a secondary clinical feature in some
OS/MDF-related pathologies, such as the mitochondrial dis-
ease, MELAS [17], and genetic diseases, as Fanconi anaemia
[55] and Werner syndrome [71].
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5. Neurologic and Neuropsychiatric Diseases
The relevance and implications of MDF and OS has been
investigated in a number of CNS-related diseases, as sum-
marized Table 4. Disease-specific abnormalities in terms of
OS/MDF are highlighted below.
5.1. Neurologic Diseases
5.1.1. Alzheimer’s Disease. Alzheimer’s disease (AD) is char-
acterized by 𝛽-amyloid deposition as a major neuropatho-
logical hallmark, which is related to a complement of OS-
related alterations, such as oxidative damage to DNA, RNA,
proteins, and lipids in synapses.Moreover, CoQ10 andMitoQ
decrease OS endpoints and Fe metabolism in AD cells [134–
136]. Concomitant MDF relates to OXPHOS alterations,
that is, loss of Complex IV, and Complex V is oxidatively
damaged and functionally altered. Mitochondria-associated
ER membranes were found to be significantly increased
in AD cells [134–139]. A recent paper reported on the 4-
HNE-induced oxidation of lipoic acid that, in turn, affects
lipoamide dehydrogenase, whose expression is significantly
decreased in brains from human AD patients and from AD
mice [138]. Zarrouk et al. [140] reported lipid alterations in
AD patients that related to peroxisomal dysfunctions, via
a cortical accumulation of saturated very long chain fatty
acids (VLCFA), substrates for peroxisomal 𝛽-oxidation. This
study investigated the effects at the mitochondrial level of
VLCFAs that were tested on human neuronal SK-NB-E cells
and found an inhibition of cell growth and mitochondrial
dysfunctions that were observed by cell counting with try-
pan blue, MTT assay, and measurement of ΔΨ. VLCFA-
treated-cells displayed stimulation of OS, along with lower
levels of mitochondrial Complexes III and IV, changes of
the cytoplasmic distribution of mitochondria, presence of
large mitochondria, and enhancement of the mitochondrial
mass [140]. The key involvement of peroxisomes in AD
was reported by Kou et al. [141] in human postmortem
brains; the patients were grouped into three cohorts of
increasing severity (stages I-II, III-IV, and V-VI, resp.), based
on the neuropathological Braak staging for AD on one
hemisphere. Lipid analyses of cortical regions from the other
hemisphere revealed accumulation of C22:0 and VLCFA,
C24:0 and C26:0, all substrates for peroxisomal 𝛽-oxidation,
in cases with stages V-VI pathology compared with those
modestly affected (stages I-II). Confocal laser microscopy
demonstrated a loss of peroxisomes in neuronal processes
with abnormally phosphorylated tau protein, implicating
impaired trafficking as the cause of altered peroxisomal
distribution. These findings pointed to peroxisome-related
alterations in AD, which may contribute to the progression
of AD pathology [141].
5.1.2. Amyotrophic Lateral Sclerosis. Amyotrophic lateral
sclerosis (ALS) features a set of OS/MDF hallmarks. Familial
ALS accounts for approximately 10% of cases and is asso-
ciated with mutations of the gene encoding SOD-1 [142–
144]. Abnormalities were found in endoplasmic reticulum
proteins, with modifications of the Golgi network [143, 144].
Moreover, a decrease was reported in WBC glutathione
peroxidase, SOD-1 and NADPH oxidase, and dysregulated
Fe metabolism. MDF was detected in terms of decreased
Complex I and ATP/ADP ratio and abnormal mitochondrial
ultrastructure [144–146].
5.1.3. Epilepsy. Epilepsy featuresNF𝜅B-induced upregulation
of NOS II gene expression with NO-, ∙O
2
−-, and ONOO−-
dependent decrease of Complex I activity and increased
Complex-III-dependent ∙O
2
− production of epileptic brain
mitochondria; seizure-related ROS formation and a protec-
tive effect of acetyl-l-carnitine indicate concomitant OS in
epilepsy [147–150].Decrease of lipoic acid synthetase suggests
inhibition of Krebs cycle along with defective mitochondrial
energy metabolism [149].
5.1.4. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS) both display OS and MDF hallmarks. Patients
with ME/CFS showed excess urinary 8-OHdG, plasma
lipid peroxides and serum oxidized LDL and decreased
vitamin C, along with decreased vitamin E and HSP70.
Mitochondria from ME/CFS patients displayed lower-
than-normal CoQ10 levels, whereas ATP production was
increased, and Complexes I, III, and IV activities were
overexpressed [151–156].
5.1.5. Multiple Sclerosis. Multiple sclerosis displays a number
of OS hallmarks, such as increasedWBC luminol-dependent
chemiluminescence, carbonyl protein andMDA, nitric oxide
metabolites, and total antioxidant capacity [157, 158]. Mela-
tonin induced increased SOD and GPx and decreased MDA
levels. The occurrence of MDF was shown by decreased
OXPHOS activity and by mtDNA deletions and reduced
PGC-1𝛼, a transcriptional coactivator andmaster regulator of
mitochondrial function [158–160].
5.1.6. Parkinson’s Disease. A pioneering report by Di Monte
et al. in 1992 suggested a link between the observation of
decreased GSH levels in Parkinson’s disease and MDF [6].
More recent studies have found a number of altered OS-
related endpoints, namely, excess plasma F2-isoprostanes,
hydroxyeicosatetraenoic acid products, cholesterol oxidation
products, neuroprostanes, phospholipase A2 and platelet
activating factor-acetylhydrolase activities, urinary 8-OHdG,
and dysregulated Femetabolism [161, 162]. Evidence forMDF
was provided by observations of decreased Complex V and
CoQ10 levels, enhanced oxidation of cysteine residues within
Complex I, and excess lactate [163–165].
5.2. Psychiatric Diseases
5.2.1. Autistic Spectrum Disorders. Autistic spectrum disor-
ders (ASD) include a group of paediatric and adolescent
diseases that display a number of OS and MDF hallmarks.
Extensive evidence forOS andNS in cells and biological fluids
from ASD patients was reported by several independent
studies, including decreased GSH :GSSG ratio in WBC and
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excess lipid peroxidation (4-HNE) in plasma and in RBC
membranes [166–168].Moreover, increased protein andDNA
damage (3-nitrotyrosine, 3-NT, and 8-OHdG) was reported
in frozen samples from necroptic cerebellum and temporal
cortex of individuals with ASD [169]. The occurrence of
bothMDF in ASD patients includes downregulation of genes
involved in electron transport chain (decreased Complex
I, III, IV, and V) and in Krebs cycle (decreased aconitase
expression), Mitochondrial DNA damage was reported, in
terms of OS-mediated mtDNA deletions and transitions,
namely, GC→AT and GC→TA [170–172]. Altogether, the
established evidence for OS/NS/MDF in ASD patients sets
realistic grounds for clinical interventions aimed at counter-
acting these metabolic imbalances in ASD patients.
5.2.2. Bipolar Disorder. Evidence for OS in bipolar disorder
(BD) has been provided in terms of lipid peroxidation and
reduced Na+-K+-ATPase activity, which can be counteracted
by lithium treatment [173]. Moreover, decreased plasma
levels of total glutathione and GSH, together with lower
catalase expression, increased protein carbonyls, 4-HNE, and
3-NT were found in BD patients [174, 175]. Mitochondrial
abnormalities in BD patients displayed decreased attachment
of hexokinase 1 to outer mitochondrial membrane and
decreased Complex I levels [175].
5.2.3. Major Depression. Major depression (MD) has been
reported to be associated with OS and with inflammation
endpoints, namely, excess levels of IL-6, IL-10, and IL-6/IL-
10 ratio versus F2-isoprostanes, along with increased protein
carbonylation and expression of GR, GPx, SOD, and CAT
[176–178]. A study of postmortem prefrontal and parieto-
occipital cortices of MD patients revealed downregulated
mRNA and protein levels of Complex I subunits (NDUFV1,
NDUFV2, and NADUFS1) [179].
5.2.4. Obsessive-Compulsive Disorder. Obsessive-compulsive
disorder (OCD) features some OS hallmarks, as excess
MDA/TBARS and SOD-1, along with decreased GSH :GSSG
ratio [180, 181]. A study reported on a shift in mitochondrial
SOD-2 genetic subtype, with increased prevalence of the
TBARS-related CC (Ala/Ala) genotype versus CT (Ala/Val)
genotype in OCD patients that was significantly lower than
in healthy donors [182].
5.2.5. Schizophrenia. An extensive body of evidence points to
the occurrence of OS, NS, and proinflammatory condition
in schizophrenia (SZ) [183]. In particular excess lipid per-
oxidation, damage to proteins and DNA, decreased plasma
total antioxidant status, and antioxidant levels (Trx, CoQ10,
Vit. E, GSH, and melatonin) were observed in SZ patients,
along with autoimmune responses, as excess IL-6 and PCC
levels [184–186]. An involvement of MDF in SZ pathogenesis
is shown by a recent report on a significant decrease in
Complex I activity both versus health donors and versus BD
patients [186] and suggested by the abovementioned decrease
in CoQ10 levels [187].
6. Cancer
A huge body of literature—of over 12,000 MedLine
citations—associates malignancies of several organs and
tissues with OS/MDF. While recognizing the outstanding
differences in the pathogenesis of different malignancies;
however general remarks to the involvement of OS/MDF
in carcinogenesis may be provided, as reviewed recently
[188, 189]. AnOS condition produces irregular cellmembrane
borders as a result of lipid peroxidation, breaks, and con-
siderableDNAdamage, resulting inmutations and eventually
cancer, via oncogene activation or tumour suppressor gene
inactivation. These mutations may initiate carcinogenesis.
Once initiated cellular transformation, cancer cells display
an increased anaerobic glycolysis enabling to support
neoplastic proliferation (Warburg effect) [190]. During
cancer promotion, hypoxic condition prevents pyruvate,
produced by anaerobic glycolysis, to be converted into
Acetyl-CoA and to enter into Krebs cycle (MDF). The
accumulated pyruvate is disposed through an alternative
pathway which leads to the formation of lactate, which
decreases microenvironmental pH. In this phase, therefore,
glycolysis is not affected by hypoxia and continues producing
pyruvate and reaction intermediates useful to the pentose
phosphate pathway that lead to the ultimate synthesis
of purine and pyrimidine bases, essential to cellular
high replicative activity. Thus, Krebs cycle is affected
by hypoxia and stops. During cancer progression, acid
microenvironment promotes tumour angiogenesis. The
restored oxygen supply activates aerobic glycolysis but the
cells continue to produce lactic acid even in presence of
oxygen and MDF endures. Further microenvironmental
acidification was related to the metastatic phenomenon
[189].
Brief examples of some selectedmalignancies will be cited
herein, as shown in Table 5. Though relevant, literature on
the involvement of OS/MDF in preneoplastic lesions (e.g.,
leukoplakia) or cancer-predisposing diseases (e.g., hepatitis
C) is not cited here.
6.1. Bladder Cancer. Evidence for OS and NS hallmarks
in bladder cancer was provided by excess oxidative DNA
damage (8-OHdG), 3-NT, and by peroxiredoxin 4 (Prdx4)
upregulation that were associated with poor prognosis [191,
192]. An involvement ofMDF in bladder cancer was reported
by finding excess mtDNA mutations (G8697A, G14905A,
C15452A, and A15607G) [193] and altered mitochondrial
expression profile of proteins involved in OXPHOS, glycol-
ysis/gluconeogenesis, and Krebs cycle [194].
6.2. Breast Cancer. Extensive studies have focused on the
involvement of OS/MDF in breast cancer pathogenesis
[195–197]. Among OS endpoints, excess 8-OHdG and pro-
tein carbonyl were reported, along with upregulated total
SOD, SOD-1, and EC-SOD in plasma and breast tumours.
Moreover, BRCA1 mutations were found to cause OS in
tumour microenvironment [198, 199]. Implications for MDF
in breast cancer include upregulation of >95 gene transcripts
associated with mitochondrial biogenesis and/or translation.
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Moreover, phosphorylated BRCA1 was found to locate to
mitochondria, and disease progression-related decreased
CoQ10 levels and SOD-2 expression were reported [199–201].
6.3. Cervical Cancer. Cervical cancer features excess lipid
peroxidation, with overexpressed GPx and decreased SOD
and CAT expression [202–206]. Null mutations in GSTM1
and GSTT1 polymorphisms were associated with excess risk
of cervical neoplasia [207]. Mitochondrial Prdx3 was found
to be overexpressed in high-risk patients [208].
6.4. Colorectal Cancer. Colorectal cancer (CrC) is character-
ized by excess oxidative DNA damage (8-OHdG) that was
correlated to CD80 mRNA mucosal levels; SOD, GR, and
GPx overexpression was observed, with GST inhibition [209,
210]. The relative mtDNA copy number showed a U-shaped
association versus CrC risk [211].
6.5. Endometrial Cancer. Endometrial cancer (EC) features
OS-related anomalies by decreased SODandCATexpression,
along with increased lipid hydroperoxides and glutathione
reductase (GR) [212]. In type I EC the occurrence of
pathogenic tumour specific mtDNA mutations as well as
a reduction of assembled Complex I in tumour samples
were found associated with an activation of antioxidant
enzymes and with an increase of mitochondrial biogenesis.
Tissue from EC showed doubling citrate synthase activity, the
mitochondrial DNA content, and the TFAM level [213, 214].
6.6. Gastric Cancer. Gastric cancer features excess 8-OHdG
levels and decreased expression of 8-oxoguanine glycosylase
(OGG-1) [215, 216]. An involvement ofMDF in gastric cancer
was suggested by SOD-2 overexpression and by the recent
report that found H. pylori-induced mtDNA mutations and
a decrease of mtDNA content [215, 217].
6.7. Hepatocellular Carcinoma. Hepatocellular carcinoma
(HCC) has been investigated extensively for its pathogenetic
implications of OS/MDF, also related to other nonneoplastic
or preneoplastic liver disorders [218–221]. AmongOS-related
hallmarks, HCC was found to display excess 8-OHdG and 4-
HNE associated with microvessel density, vascular endothe-
lial growth factor, and Akt activity; moreover, d-ROM, 𝛼-
fetoprotein, and fasting plasma were associated with HCC
recurrence [218, 219]. Implications of MDF were reported
by the association of mitochondrial SOD-2 and Trx versus
patients’ survival rate and by excess mtDNA 9-bp deletion
polymorphism in HCC patients [220, 221].
6.8. Lung Cancer. A number of studies provided extensive
evidence for the involvement of OS and MDF in lung
cancer (LC) [222–228]. The altered OS endpoint found in
LC included excess aldehyde levels, both in plasma MDA
and in exhaled breath, and with decreased serum antioxidant
capacity. Oxidative DNA damage was both reported as excess
levels of 8-OHdG and of thymidine glycol in ever-smokers. A
recent meta-analysis confirmed a strong association between
a variant OGG1 Ser326Cys and the risk of developing lung
cancer, stressing the role of oxidative DNA damage repair in
this clinical setting [223, 227]. Moreover, haeme oxygenase-
1 (HO-1) was found overexpressed, while CAT and carbonic
anhydrase were downregulated [223–225]. An involvement
of MDF in LC was associated with decrease in mtDNA and
lower-than-normal CoQ10 levels; moreover, mt HSP90s was
associated with worse clinical outcome; mitochondria were
found to display increased ΔΨ [226–228].
6.9. Melanoma. An increased oxidative DNA damage (8-
OHdG) was found in melanoma patients’ cells that was
associated with a poor prognosis, with increased NOS1
polymorphism (rs2682826) and increased TNF-𝛼 levels
enhancing the action of tumour-associated macrophages
[229–231]. Mitochondria from metastatic melanoma cells
displayed increased expression of OXPHOS activities versus
nonneoplastic melanocytes [232].
6.10.Myeloid Leukaemias. Blood cell malignancies have been
extensively investigated for the pathogenetic implications
of OS/MDF; however most of this literature appears to be
focused on myeloid leukaemias (ML); thus the literature in
this subject regarding lymphoid leukaemias is omitted. A
number of studies have provided substantial evidence for OS
hallmarks in ML, including excess lipid peroxides (measured
as MDA, TBARS, and LOOH) and protein carbonyls and
decreased thiol plasma levels and ferric reducing ability of
plasma (FRAP); moreover, increased expression of CAT,
Trx, adenosine deaminase, and xanthine oxidase, along with
decreased Prdx4 were reported, and GSTP1 Ile105Val poly-
morphism was associated with ML [233–238]. Anomalies
in mitochondrial structure and function in ML included
a disease-related 2- to 50-fold increased amplification of
mtDNA, survival advantage in patients with SOD-2 T versus
C polymorphism (in codon 16 of the mitochondrial targeting
sequence of SOD-2), and a decrease in mitochondrial-
encoded genes against an increased mtDNA copy number
[239–241].
6.11. Oral Cancer. Oral cancer displays both OS and NS
hallmarks, with excess MDA and NO levels, and AGEs levels.
Decreased CAT and SOD expression was found in OC tissue,
while SOD expression was enhanced in erythrocytes [242–
245]. As an indicator of MDF, somatic mutation of D-loop of
mtDNA was associated with better survival [246].
6.12. Thyroid Oncocytic Carcinoma. Thyroid oncocytic carci-
noma (TOC) is characterized by mitochondrial hyperplasia
and harbours high loads of disruptive mtDNAmutations, the
large majority in respiratory Complex I genes. The analysis
of a TOC cell line (XTC.UC1) displayed a complete loss of
Complex I, a reduced rate of respiration and ATP synthesis
driven by Complex I substrates, and an increase of ROS
production [247, 248].
7. Autoimmune Diseases
This class of diseases (Table 6) is characterized by a number
of OS-related hallmarks; as for MDF, most of abnormalities
may be ascribed to antimitochondrial autoantibodies (AMA).
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Thus, most of the observed MDF endpoints are secondary to
AMA-induced damage.
7.1. Antiphospholipid Syndrome. Antiphospholipid syndrome
(APS) features a set of OS- and inflammation-related altered
endpoints, including excess serum amyloid A, C-reactive
protein, 8-isoprostane and prostaglandin E2, increased per-
oxide production, nuclear abundance of Nrf2, and decreased
antioxidant enzymatic activity and intracellular GSH [249].
Mitochondria from APS patient cells displayed altered ΔΨ;
moreover, beneficial effects of CoQ10 supplementation were
observed, by improving the preservation of mitochondrial
ultrastructure [250].
7.2. Pemphigus Vulgaris. Pemphigus vulgaris displays OS-
related alterations including excess lipid peroxidation
(MDA), decreased antioxidant levels (Vit. A and E), and
altered expression of CAT and GPx [251–253]. Autoanti-
bodies against mitochondrial, desmosomal, and other
keratinocyte self-antigens were reported [253, 254].
7.3. Primary Biliary Cirrhosis. Patients with primary biliary
cirrhosis (PBC) display decreased levels of antioxidant vita-
mins (A, C and E), excess HOCl release associated with
eosinophil peroxidase, and decreased GST expression [255–
257]. The autoimmune condition in PBC was found to
show IgG production against lipid peroxides and serum and
saliva AMA against E2 subunits of 2-oxoacid dehydroge-
nase enzymes (pyruvate dehydrogenase complex, 2-oxo-acid
dehydrogenase, and 2-oxo-glutarate dehydrogenase) point-
ing to autoimmune onset of MDF [258].
7.4. Psoriasis. This disorder features a number of OS- and
NS-related hallmarks including excess lipid peroxidation
(MDA and LOOH), oxidative DNA damage (8-OHdG), and
nitrogen oxides (NOx) levels, with decreased total antioxi-
dant status and GSH levels. Decreased expression of CAT,
SOD, andGPxwas observed [259–261].Moreover,mitochon-
drial damage could be inferred by release of mitochondrial
cytochrome c and by upregulated CYP4F8mRNA [262, 263].
7.5. Rheumatoid Arthritis. Rheumatoid arthritis was found
to display excess lipid peroxide levels, along with increased
expression of myeloperoxidase and excess ROS production
in neutrophils from peripheral blood and synovial infiltrate.
This finding was related to downregulation of CAT, SOD, and
GPx and decreased GSH levels, along with TNF-𝛼-associated
ER stress. Immune imbalance included excess AGE-IgG and
chemokine (MCP-1/CCL2, RANTES/CCL5)-associated ROS
[264–268]. Mitochondrial damage was reported as mtDNA
mutations that were positively correlated with macroscopic
synovitis [269].
7.6. Sjøgren’s Syndrome. A number of OS- and NS-related
hallmarks characterize Sjøgren’s syndrome (SS) patients,
including excess protein carbonyls and AGEs, 4-HNE, TNF-
𝛼, MPO, and 3-NT; moreover, excess 8-OHdG and hexanoyl-
lysine were found in SS patients. Excess expression of Trx,
LDH and mitochondrial GOT were found in these patients
[270–273]. An autoimmune-based MDF was reported by
finding antimitochondrial autoantibodies in SS patients’
saliva [274].
7.7. Systemic Lupus Erythematosus. Systemic lupus erythe-
matosus patients display a set of OS hallmarks, such as
decreased CAT, SOD, and GPx expression, with decreased
GSH levels, and excess chemokine-associated ROS pro-
duction [275, 276]. Defective mitochondrial function was
related to lower-than-normal ATP levels, increased ΔΨ, and
persistent mitochondrial hyperpolarization [264, 276].
7.8. Systemic Sclerosis. Patients with systemic sclerosis (SSc)
display some altered OS endpoints that include excess MDA,
dityrosines, and carbonyls, with lower-than-normal uric acid
levels, GSH, and total antioxidants status in saliva. Decreased
SOD expression was accompanied by increased GPx expres-
sion [277–279], and mitochondrial damage was associated
with high-sensitivity C-reactive protein and AMA in SSc
patients [280].
7.9. Vitiligo. Vitiligo patients feature a set of OS-related
hallmarks, such as excess 4-HNE with decreased cardiolipin
and GSH levels. A decreased expression of MPO, GST, and
CAT was reported, and GST polymorphism displayed excess
GSTM1 null and GSTT1/GSTM1 double-null type [281, 282].
An involvement of MDF in vitiligo was suggested by altered
OXPHOS lipid-dependent subunits [283].
8. Miscellaneous Pathologies
Two disorders and a pathologic condition that could not be
ascribed to the above disease classifications are discussed for
their pathogenetic implications of OS/MDF in Table 7.
8.1. Cataract. Patents with cataract display excess lipid per-
oxidation (TBARS) with decreased thiol levels and ferric
reducing/antioxidant power; moreover, an increase in dehy-
droascorbate/ascorbate ratio was observed [284, 285]. A
study of polymorphisms of SOD-1, CAT, and GPx genes
in cataract patients found that G/G genotype of the SOD-1
(251A/G polymorphism) was associated with an increased
risk of cataract [286]. Several reviews discuss the roles of
mitochondria in cataract pathogenesis [287], and a H
2
O
2
-
specific induction of mitochondrial Prdx3 in the eye lens was
observed [288].
8.2. Fibromyalgia. Fibromyalgia (FM) is characterized by
excess lipid peroxidation and TNF-𝛼 levels, with loss of total
antioxidant capacity [289–291]. A line of studies by Cordero
and his colleagues has focused on MDF in FM, reporting on
decreased ΔΨ and CoQ10 levels, along with excess mt ∙O
2
−
production and excess mitophagy [291–293].
8.3. Malformations. When mechanistic aetiology is avail-
able, malformations may occur as a result of exposures to
xenobiotics before or during pregnancy (reviewed in [294]),
or some organ-specific malformations may be ascribed to
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Table 7: Miscellaneous pathologies displaying OS/MDF hallmarks.
Diseases/conditions OS/MDF hallmarks References
Cataract
↑ TBARS; ↓ thiols; ↓ ferric reducing/antioxidant power;
[284–288]↑ dehydroascorbate/ascorbate; ↑ G/G genotype of SOD-1—251A/G
polymorphism; H2O2-specific induction of Prdx3 in the eye lens
Fibromyalgia ↑ lipid peroxidation; ↓ total antioxidant capacity; ↑ TNF-𝛼; [289–293]
↓ ΔΨ; ↓ CoQ10; ↑mt ∙O
2
−; excess mitophagy
Malformations
OS and MDF in teratogenic action; thalidomide causes embryonic DNA
[294–300]
oxidation in susceptible but not resistant species; GSH depletion, or inhibition
of GPx or GR; ↓mt NADH oxidase in teratogen-sensitive embryonic tissues;
ethanol upregulates NOX regulatory subunits and increases NOX expression;
↓ complex I and IV and ATP synthase in fetal alcohol syndrome
endogenous mechanisms in the phenotype of some genetic
diseases, as for example, Fanconi anaemia (reviewed in [55]).
Whether teratogenic outcomes derive from exogenous or
endogenous factors, a vast body of literature has focused
on OS- and MDF-related pathogenetic mechanisms. The
induction of developmental defects and malformations has
been associated with OS and MDF in teratogenic action
[295]. Thalidomide was reported to cause embryonic DNA
oxidation in susceptible yet not in resistant species, which
was associated with GSH depletion, or inhibition of GPx
or GR, and with decreased mitochondrial NADH oxidase
in teratogen-sensitive embryonic tissues [296, 297]. Ethanol
was reported to upregulate NOX regulatory subunits and
increases NOX expression [298]. An involvement of MDF
in developmental anomalies was suggested by alterations of
mitochondrial respiration [299] and by reduced activities of
respiratory chain Complexes I and IV and ATP synthase in a
murine model of fetal alcohol syndrome [300].
9. Discussion
“Free radical theories” have been proposed for ageing since
1956 by Harman [301, 302] and subsequently for some high
impact disorders as cardiovascular diseases [303], diabetes
[304], and neurodegenerative diseases [6, 305–307]. Almost
sixty years after Harman’s hypothesis, many individual
disorders—or groups of interrelated disorders—have been
investigated for the implications of OS in their respective
pathogeneticmechanisms. An important step in this research
line was provided by the recognition, in 1990s, of the direct
association of MDF with OS [3–5].
In spite of the outstanding information accumulated in
these decades, one may notice that the database is usually
confined to each medical discipline and, to the best of our
knowledge, a comprehensive and interdisciplinary view is
still missing or partial. Moreover, the clinical management of
severalOS/MDF-related disorders often disregards this infor-
mation, by failing to adopt therapeutic or chemopreventive
means targeted to compensate OS/MDF.
Among the OS-related endpoints, the most commonly
observed abnormalities across broad-ranging disorders were
found by means of (a) oxidation products of biomolecules,
including lipid peroxidation products, DNA hydroxyl
adducts, advanced glycation end-products, and protein
carbonyls; (b) abnormal expression or regulation of
antioxidant activities, namely, SOD, CAT and glutathione-
related activities (GR, GPx, GST), (c) glutathione levels and
GSH:GSSG ratio, and (d) defects in iron metabolism.
Definitely less investigated than OS, the NS-related end-
points, as 3-nitrotyrosine and NO bioactivity, have been
reported to be associated with other redox-related anoma-
lies in some diseases, such as diabetes [127, 128], bladder
cancer [191], autism [169], schizophrenia [183], and Sjøgren’s
syndrome [271]. Albeit relatively unexplored, the subject of
nitrosative damage deserves higher attention in further stud-
ies, as NS-related endpoints might provide precious insights
in the pathogenesis of several OS/MDF-related disorders.
Almost invariably, MDF hallmarks were detected in OS-
related disorders in the evaluated literature, thus providing
an overall pattern of an OS/MDF association, as expected
on the grounds of a MDF-related onset of OS [3]. The most
frequently observed changes in MDF, and in mitochondrial
ultrastructure, included (a) changes in one or more activities
of the electron transport chain, OXPHOS, that is, Complexes
I to V; (b) decreased expression of Krebs cycle-associated
activities; (c) defects in mitochondrial SOD-2 and/or Prdx3
expression; (d) mtDNA deletions, decreased mtDNA copy
numbers and mitophagy [307]; (e) decreased levels of CoQ10
and/or of ATP; (f) changes in lactate/pyruvate ratio; and (g)
changes in mitochondrial membrane potential (ΔΨ). Alter-
ations in OXPHOS activities were most commonly reported
across a broad range of disorders displaying MDF hallmarks.
Relatively few studies reported on changes in Krebs cycle-
related activities, such as pyruvate dehydrogenase and pyru-
vate kinase in ageing [105], lipoamide dehydrogenase in
Alzheimer’s disease [138], lipoic acid synthetase in epilepsy
[149], and aconitase in Friedreich ataxia [87]. Another rel-
evant biomarker of MDF, SOD-2 expression, was reported
to be increased in gastric cancer [215] and hepatocellular
carcinoma [220]; SOD-2 activity was found increased in
atherosclerosis [111], type 2 diabetes mellitus [131], and upreg-
ulated SOD-2 transcripts in Hutchinson-Gilford syndrome
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[61]. Altogether, the observed overexpression or upregulation
of SOD-2 may suggest a homeostatic response in mitochon-
drial redox balance. The mitochondrial peroxidases, Prdx3
and Prdx4, were found to display expression changes in
bladder cancer that related to disease prognosis [191], and
Prdx3 upregulation was associated with increased cervical
cancer risk [208]; H
2
O
2
-induced Prdx3 overexpression was
observed in the eye lens in cataractogenesis [288]. Prdx4
was downregulated in acute promyelocytic leukemia [237]
and Prdx3 overoxidization was reported in ageing [105];
moreover, Prdx3 was found to be downregulated in cells from
Fanconi anaemia (FA-G) [57]. Unlike SOD-2, mitochondrial
peroxiredoxins show different patterns of up- or downreg-
ulation in different disorders; however their pathogenetic
roles deserve being elucidated in forthcoming studies of other
OS/MDF-related disorders.
As another possibly sensitive endpoint in evaluating
MDF, CoQ10 levels have been found lower than normal in
an extensive number of disorders, including genetic diseases
(Down syndrome, xeroderma pigmentosum, and Friedreich
ataxia) [48, 73, 86], lung cancer [223], neurologic diseases
(myalgic encephalomyelitis/chronic fatigue syndrome and
Parkinson’s sisease) [153, 162], and fibromyalgia [291]. These
data, though confined to some selected disorders, concur
with the most frequent findings of deficiencies in OXPHOS-
related activities in most of the diseases where MDF was
reported. It should be considered that measurements of
CoQ10 levels in patients with OS/MDF-related disorders
should be viewed as a preliminary step in view of possible
clinical interventions using CoQ10.
Unlike OXPHOS, only few studies have reported on
abnormalities in Krebs cycle-related endpoints. In Alzheim-
er’s disease, a decreased expression of lipoamide dehydro-
genase was detected in brain of both AD patients, and of
AD mice, along with the observation of 4-HNE-induced
oxidation of 𝛼-lipoic acid (ALA) [138]. Ageing was also
associated with deficiencies in Krebs cycle-related endpoints,
as tissue cells and skin fibroblasts of old donors displayed
decreased expression of pyruvate dehydrogenase, pyruvate
kinase, and lactate dehydrogenase [106]. A lipoic acid syn-
thetase deficiency was detected in neonatal-onset epilepsy
[149]. Quite surprisingly, no study was found in this review
reporting on ALA levels, although analytical means for
ALA measurement [308] and assay kits are available. This
information gap should be filled in forthcoming studies both
aimed at elucidating disease pathogenesis and in view of
appropriate design for clinical trials using ALA.
Mitochondrial DNA was found to be affected by point
mutations or by deletions both in primary and secondary
mtDNA-related diseases (Table 1). Several other disorders,
however, displayed mtDNA damage or changes, as mtDNA
copy number or mitophagy [307]. A recent paper by Napoli
el al. [171] reported on OS-mediated deletions mtDNA
in autistic children; damaged and mutated mtDNA was
detected in ageing cells [104–106]; among malignancies,
breast, endometrial, gastric, hepatocellular, lung, and thyroid
cancers were associated with dysregulation of mtDNA genes
or of markers of mitochondrial biogenesis [199, 213, 214, 219,
228, 247, 248]; moreover, mtDNA damage was reported in
cardiovascular disorders [112] and in osteoarthritis [122–124].
Other two markers of MDF, either mitochondrial membrane
potential (ΔΨ) or mitochondrial ultrastructure, were found
to be altered in several disorders, including Fanconi anaemia
[57–59], Down syndrome (see [49, 52], reviewed in [309]),
and fibromyalgia [291, 292].
Far from being confined to the classically termed mito-
chondrial diseases, the present information points to the
association of MDF with OS and, to a limited extent, with
NS across a number of diseases pertaining to broad-ranging
medical disciplines. Thus, one may imagine treasuring the
current knowledge of mitochondrial diseases in order to
design appropriate interventions in several pathologies. In
this prospect, the cofactors recognized as “mitochondrial
nutrients,” as ALA, CoQ10, and l-carnitine (CARN) (or its
derivatives) [310, 311] should be regarded as a prime tool
in mitigating MDF and, hence, OS in several disorders; a
line of ongoing clinical studies is foreseen by at least one
extensive study group focused on mitochondrial diseases,
on the grounds of the novel discipline termed “mitochon-
driology” [312, 313]. The present and growing awareness for
the pathogenetic roles of OS/MDF in several disorders has
prompted a number of clinical groups to undertake clinical
trials testing mitochondrial nutrients aimed at counteracting
OS/MDF in patients with an extensive number of diseases.
The current knowledge of previous clinical trials and the
prospects of study design are reported in a parallel review to
the present paper [314].
10. Conclusion
The association of MDF with OS and, probably, NS is a
widespread phenomenon encompassing a broad number
of different disorders. The current knowledge of mito-
chondrial diseases and of other OS/MDF related diseases
should prompt further investigations to elucidate the roles of
OS/MDF in a number of disorders, in the prospect of rational
interventions aimed at mitigating OS/MDF-related clinical
progression.
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